AWM Investment Company Inc. Grows Stake in Progyny, Inc. (NASDAQ:PGNY)

AWM Investment Company Inc. raised its holdings in Progyny, Inc. (NASDAQ:PGNY) by 540.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 160,000 shares of the company’s stock after buying an additional 135,000 shares during the quarter. AWM Investment Company Inc.’s holdings in Progyny were worth $2,760,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in PGNY. Signaturefd LLC boosted its holdings in Progyny by 1,355.0% in the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock valued at $25,000 after acquiring an additional 1,355 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after purchasing an additional 1,526 shares during the period. Caitlin John LLC boosted its stake in shares of Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after purchasing an additional 3,183 shares in the last quarter. Natixis purchased a new position in shares of Progyny during the fourth quarter valued at about $69,000. Finally, SBI Securities Co. Ltd. bought a new position in Progyny in the fourth quarter worth about $74,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on PGNY. JPMorgan Chase & Co. lifted their price objective on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, January 28th. Canaccord Genuity Group reduced their price target on Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, May 12th. BTIG Research upgraded Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Monday, March 31st. Finally, Bank of America upped their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.45.

Progyny Stock Performance

Shares of PGNY stock opened at $21.87 on Wednesday. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 37.71, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37. Progyny, Inc. has a one year low of $13.39 and a one year high of $30.42. The company’s 50-day moving average is $22.15 and its 200 day moving average is $19.85.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.45 by ($0.28). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The firm had revenue of $324.04 million for the quarter, compared to analysts’ expectations of $307.86 million. During the same quarter in the previous year, the company earned $0.17 EPS. The company’s quarterly revenue was up 16.5% compared to the same quarter last year. As a group, research analysts predict that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.